Cannabidiol

Is Portugal's cannabis market hitting the brakes? 📉🇵🇹 Recent cuts in licensing have visibly contracted the sector — reducing new entrants, cooling investment, and creating supply and patient-access pressures while forcing companies to reassess growth strategies. The article explains the regulatory shifts, market impacts, and what policymakers and businesses can do next. Read the full analysis to understand the implications and next steps for stakeholders. #SyenzaNews #regulatoryaffairs #pharmaceuticals #MarketAccess #governance

Cannabidiol has been licensed as an add-on treatment for seizures caused by tuberous sclerosis complex for patients aged 2 years and over. Clinical trial evidence shows that it reduces seizure frequency and increases seizure-free days compared to a placebo. While the cost-effectiveness estimates are uncertain, the benefits of reducing the severity of seizures and lowering the risk of sudden unexpected death in epilepsy make it an appropriate use of NHS resources. Therefore, it is recommended as a treatment option by […]